ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Novembro 2023 - 5:30PM
Business Wire
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the compensation committee of the Company’s
Board of Directors (the “Compensation Committee”) approved,
effective as of October 31, 2023, grants of non-qualified stock
options to purchase 2,650 shares of its common stock and restricted
stock units (“RSUs”) covering 1,800 shares of its common stock
under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as
amended (the “Inducement Plan”) to a new employee.
The Inducement Plan is used exclusively for the grant of equity
awards to individuals who were not previously employees of
ImmunoGen (or following a bona fide period of non-employment), as
an inducement material to such individual’s entering into
employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the
Nasdaq Listing Rules.
The options have exercise prices of $14.86 per share, which is
equal to the closing price of ImmunoGen’s common stock on the
Nasdaq Global Select Market on October 31, 2023. Each option will
vest as to 25% of the shares underlying such option on the first
anniversary of the grant date and as to an additional 6.25% of the
shares underlying the option quarterly thereafter, subject to the
employee’s continued employment on each vesting date. Each RSU will
vest as to 25% of the shares underlying the RSU award on the first
anniversary of the grant date and as to an additional 25% of the
shares underlying the RSU award annually thereafter, subject to the
employee’s continued employment on each vesting date. Each option
and RSU is subject to the terms and conditions of the Inducement
Plan and the terms and conditions of a stock option agreement and
an RSU agreement covering the respective grants.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates to improve outcomes for cancer patients. By generating
targeted therapies with enhanced anti-tumor activity and favorable
tolerability profiles, we aim to disrupt the progression of cancer
and offer our patients more good days. We call this our commitment
to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101753557/en/
INVESTOR RELATIONS CONTACT ImmunoGen Anabel Chan
781-895-0600 anabel.chan@immunogen.com
MEDIA CONTACTS ImmunoGen Courtney O’Konek 781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024